Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Ocul Immunol Inflamm. 2018 Feb 16;27(4):686–692. doi: 10.1080/09273948.2018.1424341

Figure 1: Treatment Overview.

Figure 1:

aImmunomodulatory therapy

bOther reasons for stopping include: adverse events (n=6), lack of systemic efficacy (n=2), pregnancy (n=1), cost (n=1), and unknown (n=1).